Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Feb 1;312(2):F373-F374.
doi: 10.1152/ajprenal.00499.2016. Epub 2016 Oct 19.

Stop that podocyte!

Vineet Gupta  1 , Jochen Reiser  2
Affiliations
Editorial

Stop that podocyte!

Vineet Gupta et al. Am J Physiol Renal Physiol. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
A schematic showing potential drug discovery strategies for identification of novel agents as future therapeutics for chronic kidney disease (CKD). There are 3 assay strategies for an initial (primary) screen. They all involve targeting 1 of the 3 key characteristics: cell shape, motility, and in vivo functionality. A podocyte cell-based phenotypic assay can be used to identify compounds that protect overall cellular cytoskeleton and morphology. A zebrafish-based assay can be used to screen compounds that would protect filtration barrier and kidney function. A 3rd type of assay, as described in the report by Tan et al. (5a), can be used to identify compounds that reduce injury-dependent increase in podocyte motility. Subsequently, the identified hits from each of the 3 types of campaigns could be validated in the other type of assay to select hits that affect these key podocyte qualities before testing in rodent experimental models. Selected compounds can then go through a few rounds of optimization, including target identification, mechanistic studies, and medicinal chemistry-based approaches, before entering a hit-to-lead program and be nominated as a therapeutic lead.
See this image and copyright information in PMC

Comment on

References

    1. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17: 428–437, 2007. doi:10.1016/j.tcb.2007.06.006. - DOI - PubMed
    1. Huber TB, Benzing T. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14: 211–216, 2005. doi:10.1097/01.mnh.0000165885.85803.a8. - DOI - PubMed
    1. Lee HW, Khan SQ, Faridi MH, Wei C, Tardi NJ, Altintas MM, Elshabrawy HA, Mangos S, Quick KL, Sever S, Reiser J, Gupta V. A podocyte-based automated screening assay identifies protective small molecules. J Am Soc Nephrol 26: 2741–2752, 2015. doi:10.1681/ASN.2014090859. - DOI - PMC - PubMed
    1. Reiser J, Gupta V, Kistler AD. Toward the development of podocyte-specific drugs. Kidney Int 77: 662–668, 2010. doi:10.1038/ki.2009.559. - DOI - PMC - PubMed
    1. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, Honey K, Ishidoh K, Kominami E, Kreidberg JA, Tomino Y, Mundel P. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827–34832, 2004. doi:10.1074/jbc.M401973200. - DOI - PubMed

Substances

LinkOut - more resources